{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:03:40Z","timestamp":1790334220913,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.dmd.2026.100374","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:34:07Z","timestamp":1784763247000},"page":"100374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Endogenous biomarkers for assessing CYP3A4 and CYP2D6 activity: A critical review"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4332-6549","authenticated-orcid":false,"given":"Shambhavi","family":"Parab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imam H.","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Venkataramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.dmd.2026.100374_bib1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.apsb.2019.10.001","article-title":"Current trends in drug metabolism and pharmacokinetics","volume":"9","author":"Li","year":"2019","journal-title":"Acta Pharm Sin B"},{"issue":"23","key":"10.1016\/j.dmd.2026.100374_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 enzymes and drug metabolism in humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.dmd.2026.100374_bib3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","article-title":"Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation","volume":"392","author":"Zanger","year":"2008","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.dmd.2026.100374_bib4","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.18636","article-title":"CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms","volume":"12","author":"Zhang","year":"2024","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.dmd.2026.100374_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100374_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2016.08.001","article-title":"Drug metabolism in the liver","volume":"21","author":"Almazroo","year":"2017","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.dmd.2026.100374_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1872312812666181119154734","article-title":"Use of cocktail probe drugs for indexing cytochrome P450 enzymes in clinical pharmacology studies\u2014review of case studies","volume":"13","author":"Giri","year":"2019","journal-title":"Drug Metab Lett"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/toxres\/tfae044","article-title":"New approach methodologies (NAMs): identifying and overcoming hurdles to accelerated adoption","volume":"13","author":"Sewell","year":"2024","journal-title":"Toxicol Res"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.70165","article-title":"Deconvoluting gut versus liver cytochrome P450 3A4 function: drug probes, biomarkers, and tissue biopsy","volume":"66","author":"Rodrigues","year":"2026","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100374_bib12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1177\/0091270005276202","article-title":"Effect of age and postoperative time on cytochrome p450 enzyme activity following liver transplantation","volume":"45","author":"Liu","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100374_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-2710.1999.00246.x","article-title":"Gender-related differences in pharmacokinetics and their clinical significance","volume":"24","author":"Tanaka","year":"1999","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","article-title":"National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy","volume":"192","author":"Tracy","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"23","key":"10.1016\/j.dmd.2026.100374_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315168","article-title":"Pregnancy increases CYP3A enzymes activity as measured by the 4\u03b2-hydroxycholesterol\/cholesterol ratio","volume":"23","author":"Mlugu","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100374_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2710.2009.01070.x","article-title":"Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient","volume":"35","author":"Capone","year":"2010","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2125.1998.00764.x","article-title":"Grapefruit juice\u2013drug interactions","volume":"46","author":"Bailey","year":"1998","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00609878","article-title":"Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin","volume":"15","author":"Ohnhaus","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100374_bib19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1210\/jcem-52-3-381","article-title":"6 beta-hydroxycortisol: a noninvasive indicator of enzyme induction","volume":"52","author":"Saenger","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.dmd.2026.100374_bib20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2125.1989.tb03516.x","article-title":"The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction","volume":"28","author":"Ged","year":"1989","journal-title":"Br J Clin Pharmacol"},{"issue":"42","key":"10.1016\/j.dmd.2026.100374_bib21","doi-asserted-by":"crossref","first-page":"38685","DOI":"10.1074\/jbc.M105127200","article-title":"Antiepileptic drugs increase plasma levels of 4\u03b2-hydroxycholesterolin humans: evidence for involvement of cytochrome P450 3a4","volume":"276","author":"Bodin","year":"2001","journal-title":"J Biol Chem"},{"issue":"35","key":"10.1016\/j.dmd.2026.100374_bib22","doi-asserted-by":"crossref","first-page":"31534","DOI":"10.1074\/jbc.M201712200","article-title":"Metabolism of 4 beta -hydroxycholesterol in humans","volume":"277","author":"Bodin","year":"2002","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.dmd.2026.100374_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2125.2008.03309.x","article-title":"4\u03b2-Hydroxycholesterol as an endogenous marker for CYP3A4\/5 activity. Stability and half-life of elimination after induction with rifampicin","volume":"67","author":"Diczfalusy","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100374_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/jpm11060457","article-title":"Evaluation of 1\u03b2-hydroxylation of deoxycholic acid as a non-invasive urinary biomarker of CYP3A activity in the assessment of inhibition-based drug\u2013drug interaction in healthy volunteers","volume":"11","author":"Li","year":"2021","journal-title":"J Pers Med"},{"issue":"9","key":"10.1016\/j.dmd.2026.100374_bib25","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1124\/dmd.124.001680","article-title":"1\u03b2-hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of CYP3A clinical drug-drug interaction potential","volume":"52","author":"Xue","year":"2024","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"9","key":"10.1016\/j.dmd.2026.100374_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100141","article-title":"1\u03b2-Hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of drug-drug interaction with moderate CYP3A inhibitor","volume":"53","author":"Chen","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100374_bib27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1124\/mol.111.076356","article-title":"An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway","volume":"81","author":"Wang","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmd.2026.100374_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108283","article-title":"Comparison of steroid hormone hydroxylation mediated by cytochrome P450 3A subfamilies","volume":"682","author":"Niwa","year":"2020","journal-title":"Arch Biochem Biophys"},{"issue":"5","key":"10.1016\/j.dmd.2026.100374_bib29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/00498254.2011.631224","article-title":"Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes","volume":"42","author":"Zhang","year":"2012","journal-title":"Xenobiotica"},{"issue":"10","key":"10.1016\/j.dmd.2026.100374_bib30","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1124\/dmd.122.000957","article-title":"Isolation and identification of 3,4-seco-solanidine-3,4-dioic acid (SSDA) as a urinary biomarker of cytochrome P450 2D6 (CYP2D6) activity","volume":"50","author":"Behrle","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100374_bib31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bcp.15721","article-title":"Evidence for solanidine as a dietary CYP2D6 biomarker: significant correlation with risperidone metabolism","volume":"90","author":"Wollmann","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100374_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40246-024-00579-8","article-title":"Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity","volume":"18","author":"Kiiski","year":"2024","journal-title":"Hum Genomics"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib33","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1124\/jpet.108.141796","article-title":"The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6","volume":"327","author":"Snider","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100374_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00008571-200303000-00007","article-title":"Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6","volume":"13","author":"Yu","year":"2003","journal-title":"Pharmacogenetics"},{"issue":"10","key":"10.1016\/j.dmd.2026.100374_bib35","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3390\/pharmaceutics16101284","article-title":"Applications of the cholesterol metabolite, 4\u03b2-hydroxycholesterol, as a sensitive endogenous biomarker for hepatic CYP3A activity evaluated within a PBPK framework","volume":"16","author":"Karkhanis","year":"2024","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.dmd.2026.100374_bib36","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/clpt.2011.53","article-title":"Evaluation of 6\u03b2-hydroxycortisol, 6\u03b2-hydroxycortisone and their combination as endogenous probes for inhibition of CYP3A4 in vivo","volume":"89","author":"Peng","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100374_bib37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00008571-200306000-00002","article-title":"Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase","volume":"13","author":"Yu","year":"2003","journal-title":"Pharmacogenetics"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s002280050729","article-title":"Fluvoxamine but not citalopram increases serum melatonin in healthy subjects\u2014an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin","volume":"56","author":"von Bahr","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100374_bib39","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/clpt.1983.255","article-title":"6 beta-hydroxycortisol in random urine samples as an indicator of enzyme induction","volume":"34","author":"Saenger","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2026.100374_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2020.12.001","article-title":"Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects","volume":"36","author":"Lee","year":"2021","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1-3","key":"10.1016\/j.dmd.2026.100374_bib41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbalip.2004.11.003","article-title":"Novel pathways of bile acid metabolism involving CYP3A4","volume":"1687","author":"Bodin","year":"2005","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"10.1016\/j.dmd.2026.100374_bib42","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1124\/dmd.116.070805","article-title":"CYP3A specifically catalyzes 1\u03b2-hydroxylation of deoxycholic acid: characterization and enzymatic synthesis of a potential novel urinary biomarker for CYP3A activity","volume":"44","author":"Hayes","year":"2016","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"5","key":"10.1016\/j.dmd.2026.100374_bib43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/clpt.2013.128","article-title":"Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance","volume":"94","author":"Shin","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100374_bib44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.dmpk.2019.04.002","article-title":"Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers","volume":"34","author":"Lee","year":"2019","journal-title":"Drug Metab Pharmacokinet"},{"issue":"23","key":"10.1016\/j.dmd.2026.100374_bib45","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1111\/bph.15651","article-title":"Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity","volume":"178","author":"Magliocco","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"16","key":"10.1016\/j.dmd.2026.100374_bib46","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.2217\/pgs.14.155","article-title":"Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics","volume":"15","author":"Tay-Sontheimer","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"8","key":"10.1016\/j.dmd.2026.100374_bib47","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00228-008-0492-8","article-title":"CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels","volume":"64","author":"Josephson","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100374_bib48","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00228-014-1675-0","article-title":"Comparison of two endogenous biomarkers of CYP3A4 activity in a drug\u2013drug interaction study between midostaurin and rifampicin","volume":"70","author":"Dutreix","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/chromsci\/bmac038","article-title":"Simultaneous determination of cortisol and 6\u03b2-hydroxycortisol in human plasma by liquid chromatography-tandem mass spectrometry","volume":"61","author":"Sun","year":"2023","journal-title":"J Chromatogr Sci"},{"issue":"9","key":"10.1016\/j.dmd.2026.100374_bib50","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/aps.2009.116","article-title":"Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism","volume":"30","author":"Luo","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.dmd.2026.100374_bib51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.steroids.2014.05.023","article-title":"Use of endogenous cortisol 6\u03b2-hydroxylation clearance for phenotyping in vivo CYP3A activity in women after sequential administration of an oral contraceptive (OC) containing ethinylestradiol and levonorgestrel as weak CYP3A inhibitors","volume":"87","author":"Shibasaki","year":"2014","journal-title":"Steroids"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib52","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.gastro.2005.05.009","article-title":"Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans","volume":"129","author":"Marschall","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.dmd.2026.100374_bib53","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1365-2125.2007.03078.x","article-title":"Time course of the increase in 4\u03b2-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy","volume":"65","author":"Wide","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100374_bib54","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/tpj.2012.46","article-title":"Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients","volume":"13","author":"Habtewold","year":"2013","journal-title":"Pharmacogenomics J"},{"issue":"12","key":"10.1016\/j.dmd.2026.100374_bib55","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1093\/jac\/dku286","article-title":"Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4\u03b2-hydroxycholesterol during efavirenz treatment and efavirenz\/rifampicin co-treatment","volume":"69","author":"Ngaimisi","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.dmd.2026.100374_bib56","doi-asserted-by":"crossref","first-page":"709","DOI":"10.5414\/CPP47709","article-title":"4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man","volume":"47","author":"L\u00fctjohann","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100374_bib57","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/bcp.12425","article-title":"Validation of 4\u03b2-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects","volume":"78","author":"Kasichayanula","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100374_bib58","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/bcp.12016","article-title":"A comparison of 4\u03b2-hydroxycholesterol: cholesterol and 6\u03b2-hydroxycortisol: cortisol as markers of CYP3A4 induction","volume":"75","author":"M\u00e5rde Arrh\u00e9n","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100374_bib59","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2133\/dmpk.DMPK-13-SH-138","article-title":"Quinine compared to 4\u03b2-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin","volume":"29","author":"Bj\u00f6rkhem-Bergman","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"issue":"8","key":"10.1016\/j.dmd.2026.100374_bib60","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1124\/dmd.113.052316","article-title":"Comparison of endogenous 4\u03b2-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin","volume":"41","author":"Bj\u00f6rkhem-Bergman","year":"2013","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"5","key":"10.1016\/j.dmd.2026.100374_bib61","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1208\/s12248-016-9941-y","article-title":"Urinary 6\u03b2-hydroxycortisol\/cortisol ratio most highly correlates with midazolam clearance under hepatic CYP3A inhibition and induction in females: a pharmacometabolomics approach","volume":"18","author":"Shin","year":"2016","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib62","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3390\/jpm11020150","article-title":"The 1\u03b2-hydroxy-deoxycholic acid to deoxycholic acid urinary metabolic ratio: toward a phenotyping of CYP3A using an endogenous marker?","volume":"11","author":"Magliocco","year":"2021","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib63","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1124\/dmd.112.048561","article-title":"Intraindividual and interindividual variabilities in endogenous cortisol 6\u03b2-hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans","volume":"41","author":"Shibasaki","year":"2013","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"4","key":"10.1016\/j.dmd.2026.100374_bib64","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1208\/s12248-017-0090-8","article-title":"Distribution of exogenous and endogenous CYP3A markers and related factors in healthy males and females","volume":"19","author":"Lee","year":"2017","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.dmd.2026.100374_bib65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jchromb.2009.11.023","article-title":"Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS\/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity","volume":"878","author":"Lutz","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"6","key":"10.1016\/j.dmd.2026.100374_bib66","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/00007691-200212000-00007","article-title":"A wide interindividual variability of urinary 6beta-hydroxycortisol to free cortisol in 487 healthy Japanese subjects in near basal condition","volume":"24","author":"Inagaki","year":"2002","journal-title":"Ther Drug Monit"},{"issue":"11","key":"10.1016\/j.dmd.2026.100374_bib67","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/S0022-2275(20)39708-X","article-title":"Identification and quantitation of cholest-5-ene-3 beta,4 beta-diol in rat liver and human plasma","volume":"36","author":"Breuer","year":"1995","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100374_bib68","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/abio.1995.1110","article-title":"Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry","volume":"225","author":"Dzeletovic","year":"1995","journal-title":"Anal Biochem"},{"issue":"8","key":"10.1016\/j.dmd.2026.100374_bib69","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1194\/jlr.E017806","article-title":"Still another activity by the highly promiscuous enzyme CYP3A4: 25-hydroxylation of cholesterol","volume":"52","author":"Diczfalusy","year":"2011","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib70","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1194\/jlr.M600282-JLR200","article-title":"PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine","volume":"48","author":"Li","year":"2007","journal-title":"J Lipid Res"},{"issue":"11","key":"10.1016\/j.dmd.2026.100374_bib71","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1177\/0091270009360041","article-title":"Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?","volume":"50","author":"Yang","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100374_bib72","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/FPC.0b013e3282f50ee9","article-title":"4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians","volume":"18","author":"Diczfalusy","year":"2008","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib73","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/clpt.2009.72","article-title":"Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?","volume":"86","author":"Tomalik-Scharte","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.dmd.2026.100374_bib74","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00228-022-03336-9","article-title":"Correlations between 4\u03b2-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range","volume":"78","author":"Eide Kvitne","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib75","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100374_bib76","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"10.1016\/j.dmd.2026.100374_bib77","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cld.861","article-title":"Bile acid biology, pathophysiology, and therapeutics","volume":"15","author":"Chiang","year":"2020","journal-title":"Clin Liver Dis"},{"issue":"6","key":"10.1016\/j.dmd.2026.100374_bib78","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/dmd.119.086637","article-title":"Stereoselective oxidation kinetics of deoxycholate in recombinant and microsomal CYP3A enzymes: deoxycholate 19-hydroxylation is an in vitro marker of CYP3A7 activity","volume":"47","author":"Chen","year":"2019","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"9340","key":"10.1016\/j.dmd.2026.100374_bib79","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(02)11203-7","article-title":"Clinical importance of the cytochromes P450","volume":"360","author":"Nebert","year":"2002","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.dmd.2026.100374_bib80","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1124\/dmd.117.078055","article-title":"Digging deeper into CYP3A testosterone metabolism: kinetic, regioselectivity, and stereoselectivity differences between CYP3A4\/5 and CYP3A7","volume":"45","author":"Kandel","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100374_bib81","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1124\/dmd.104.003327","article-title":"Characterization of testosterone 11 beta-hydroxylation catalyzed by human liver microsomal cytochromes P450","volume":"33","author":"Choi","year":"2005","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"3","key":"10.1016\/j.dmd.2026.100374_bib82","first-page":"342","article-title":"Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis","volume":"15","author":"Simpson","year":"1994","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib83","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2004.10.007","article-title":"Cytochrome P450-mediated metabolism of estrogens and its regulation in human","volume":"227","author":"Tsuchiya","year":"2005","journal-title":"Cancer Lett"},{"issue":"19","key":"10.1016\/j.dmd.2026.100374_bib84","first-page":"6532","article-title":"Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16alpha-hydroxylation of estrone but not 17beta-estradiol","volume":"63","author":"Lee","year":"2003","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.dmd.2026.100374_bib85","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17425255.2022.2160317","article-title":"CYP2D6 pharmacogenetics and phenoconversion in personalized medicine","volume":"18","author":"Nahid","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"23","key":"10.1016\/j.dmd.2026.100374_bib86","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1111\/bph.15651","article-title":"Metabolomics reveals five endogenous biomarkers in human urine and plasma to predict CYP2D6 activity","volume":"178","author":"Magliocco","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib87","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1124\/jpet.107.119321","article-title":"Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides","volume":"321","author":"Snider","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"26","key":"10.1016\/j.dmd.2026.100374_bib88","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1016\/j.jchromb.2009.04.016","article-title":"Targeted stable-isotope dilution GC-MS\/MS analysis of the endocannabinoid anandamide and other fatty acid ethanol amides in human plasma","volume":"877","author":"Zoerner","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.dmd.2026.100374_bib89","series-title":"Discovery and Assessment of Endogenous Biomarkers of CYP2D6 Activity for Application in Clinical Studies. Ph.D. thesis","author":"Sontheimer","year":"2015"},{"issue":"1","key":"10.1016\/j.dmd.2026.100374_bib90","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3803\/EnM.2016.31.1.7","article-title":"Understanding metabolomics in biomedical research","volume":"31","author":"Kim","year":"2016","journal-title":"Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.dmd.2026.100374_bib91","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3390\/metabo10080314","article-title":"Metabolomic biomarkers for detection, prognosis and identifying recurrence in endometrial cancer","volume":"10","author":"Njoku","year":"2020","journal-title":"Metabolites"},{"issue":"4","key":"10.1016\/j.dmd.2026.100374_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2026.100256","article-title":"Mechanism-guided untargeted-to-targeted lipidomics identifies phosphatidylcholine 38:4 in rat bile as an Abcb4\/Mdr2 inhibition marker","volume":"54","author":"Liu","year":"2026","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100374_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100204","article-title":"Unraveling enantioselective metabolism: human cytochrome P450s in arachidonic acid biotransformation","volume":"53","author":"Isse","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100374_bib94","doi-asserted-by":"crossref","first-page":"R455","DOI":"10.1530\/ERC-16-0285","article-title":"Metabolic profiling of cholesterol and sex steroid hormones to monitor urological diseases","volume":"23","author":"Moon","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.dmd.2026.100374_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1045843","article-title":"Plasma metabolomic profiling reveals factors associated with dose-adjusted trough concentration of tacrolimus in liver transplant recipients","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100374_bib96","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/toxsci\/kft143","article-title":"Identification of 2-piperidone as a biomarker of CYP2E1 activity through metabolomic phenotyping","volume":"135","author":"Cheng","year":"2013","journal-title":"Toxicol Sci"},{"issue":"5","key":"10.1016\/j.dmd.2026.100374_bib97","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/cpt.1764","article-title":"Normalized testosterone glucuronide as a potential urinary biomarker for highly variable UGT2B17 in children 7 to 18 years","volume":"107","author":"Zhang","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2026.100374_bib98","first-page":"157","article-title":"Study of the urinary ratio of 6 \u03b2-hydroxycortisol\/cortisol as a biomarker of cyp3a4 activity in Egyptian patients with chronic liver diseases","volume":"1","author":"ELDesoky","year":"2007","journal-title":"Biomark Insights"},{"issue":"3","key":"10.1016\/j.dmd.2026.100374_bib99","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1556\/APhysiol.90.2003.3.4","article-title":"Plasma 6beta-hydroxycortisol measurements for assessing altered hepatic drug metabolizing enzyme activity","volume":"90","author":"Sz\u00fccs","year":"2003","journal-title":"Acta Physiol Hung"},{"key":"10.1016\/j.dmd.2026.100374_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2020.11.003","article-title":"The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects","volume":"36","author":"Lee","year":"2021","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib101","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cpt.3436","article-title":"Utility of biomarker-informed drug interaction evaluation in drug development and regulatory decision making","volume":"117","author":"Ishiguro","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dmd.2026.100374_bib102","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1124\/dmd.124.001876","article-title":"Quantitative prediction of drug-drug interactions caused by CYP3A induction using endogenous biomarker 4\u03b2-hydroxycholesterol","volume":"52","author":"Takubo","year":"2024","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"11","key":"10.1016\/j.dmd.2026.100374_bib103","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/psp4.12348","article-title":"PBPK modeling of coproporphyrin I as an endogenous biomarker for drug interactions involving inhibition of hepatic OATP1B1 and OATP1B3","volume":"7","author":"Yoshikado","year":"2018","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100374_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100036","article-title":"Physiologically based pharmacokinetic modeling of midostaurin and metabolites at steady-state to bridge drug interaction scenarios in lieu of clinical trials","volume":"53","author":"Gu","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100374_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100109","article-title":"Prediction of CYP3A-mediated drug\u2013drug interactions using endogenous biomarkers 6\u03b2-hydroxycortisol and cortisol","volume":"53","author":"Takubo","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100374_bib106","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1046\/j.1399-0012.2003.00133.x","article-title":"The variability of liver graft function and urinary 6beta-hydroxycortisol to cortisol ratio during liver regeneration in liver transplant recipients","volume":"18","author":"Kishino","year":"2004","journal-title":"Clin Transplant"},{"issue":"9","key":"10.1016\/j.dmd.2026.100374_bib107","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1194\/jlr.P040022","article-title":"Significant increase in plasma 4\u03b2-hydroxycholesterol concentration in patients after kidney transplantation","volume":"54","author":"Suzuki","year":"2013","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.dmd.2026.100374_bib108","doi-asserted-by":"crossref","first-page":"815","DOI":"10.31083\/ph.2015.5662","article-title":"A non-invasive CYP3A4 biomarker and body mass index predict cyclosporine dosage requirements in Chinese renal transplant recipients","volume":"70","author":"Cai","year":"2015","journal-title":"Pharmazie"},{"key":"10.1016\/j.dmd.2026.100374_bib109","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.steroids.2017.09.001","article-title":"Twenty-four hour urinary cortisol excretion and the metabolic syndrome in prednisolone-treated renal transplant recipients","volume":"127","author":"de Vries","year":"2017","journal-title":"Steroids"},{"issue":"6","key":"10.1016\/j.dmd.2026.100374_bib110","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bcpt.12537","article-title":"Effect of statin treatment on plasma 4\u03b2-hydroxycholesterol concentrations","volume":"118","author":"Bj\u00f6rkhem-Bergman","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.dmd.2026.100374_bib111","series-title":"Physiology, Cortisol","author":"Thau","year":"2023"},{"issue":"1-2","key":"10.1016\/j.dmd.2026.100374_bib112","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jchromb.2005.09.007","article-title":"Simultaneous determination of 6beta-hydroxycortisol and cortisol in human urine and plasma by liquid chromatography with ultraviolet absorbance detection for phenotyping the CYP3A activity","volume":"826","author":"Hu","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100374_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100209","article-title":"Assessing hepatic impairment with biomarker-informed physiologically based pharmacokinetic modeling: Strengths and limitations of the endogenous biomarker coproporphyrin I","volume":"54","author":"Witkowski","year":"2026","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:16:28Z","timestamp":1790331388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":111,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0090955626006434"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100374","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endogenous biomarkers for assessing CYP3A4 and CYP2D6 activity: A critical review","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100374"}}